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Abstract
Background: Hemolytic anemia is a rare but reported side effect of intravenous immunoglobulin (IVIG) therapy.
The risk of significant hemolysis appears greater in those patients who receive high dose IVIG. The etiology is
multifactorial but may relate to the quantity of blood group antibodies administered via the IVIG product.
Findings: We describe 4 patients with significant hemolytic anemia following treatment with IVIG for Kawasaki
disease (KD). Direct antibody mediated attack as one of the mechanisms for hemolysis, in this population, is
supported by the demonstration of specific blood group antibodies in addition to a positive direct antiglobulin
test in our patients.
Conclusions: Clinicians should be aware of this complication and hemoglobin should be closely monitored
following high dose IVIG therapy.
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Background
KD is a systemic vasculitis in which the major compli-
cation is the development of coronary artery aneurysms
(CAA). Treatment with intravenous immunoglobulin
(IVIG) significantly lowers the incidence of CAA. Stan-
dard therapy for the treatment of KD is high dose IVIG
(2 g/kg) and aspirin. Retreatment with IVIG is adminis-
tered for persistence of fever ≥ 36 h after the first infu-
sion. Persistence of fever after initial IVIG therapy is
estimated to occur in approximately 10% - 20% of cases
[1].
IVIG is used in high doses, most frequently at 2 g/kg,
as an immunomodulatory agent [2]. It is a pooled blood
product acquired from thousands of blood donors and it
contains measurable levels of anti-A and anti-B (IgG
subclass) as well as non-ABO erythrocyte antibodies (e.
g. anti-D) [3]. IVIG is considered to be a safe product
that is generally well tolerated. Hemolysis is a rarely
reported side effect of IVIG. It occurs more commonly
in those patients who receive high-dose IVIG [2,4] as is
used in the treatment of KD. In the literature, there are
6 reported cases of children with hemolytic anemia fol-
lowing IVIG treatment for KD [4-7]. In this report, we
describe 4 patients, all from a single centre, who devel-
oped hemolytic anemia following IVIG treatment for
K D .T oo u rk n o w l e d g e ,t h i si so n eo ft h el a r g e s tc a s e
series describing this complication in this patient
population.
Findings
Significant hemolysis was noted in 4 out of 25 (16%)
patients diagnosed and treated for KD at our centre
during a 14-month interval. In this cohort of 25
patients, 9 (36%) required retreatment with IVIG for
persistent fever. This was higher than our usual retreat-
ment rate of 18% [8]. Of these 9 patients, 4 (44.4%)
developed significant hemolytic anemia and of these, 2
required blood transfusion for hemodynamic instability.
In all 4 patients, the direct antiglobulin test (IgG) was
positive. In the 3 patients tested, all demonstrated speci-
fic blood group antibodies in the eluates prepared from
their red cells (see Table 1).
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Case 1
A previously healthy 22-month old Egyptian male pre-
sented with 13 days of fever, diffuse maculopapular rash,
conjunctival injection without exudate, erythema and
edema of the hands and feet and oral mucosal changes.
The patient was diagnosed with KD and treated with
IVIG. Approximately 36 h after completion of the 1
st
IVIG, he was given a 2
nd infusion of IVIG because of
persistent fever. Significant hemolytic anemia was noted
30 h after completion of the 2
nd IVIG (see Tables 1 and
2). The patient was also treated with oral prednisone (1
mg/kg) that was tapered over 6-weeks. Two weeks fol-
lowing the diagnosis of KD, a small aneurysm of the left
anterior descending coronary artery (3.9 mm) was noted
and the child was continued on aspirin therapy.
Case 2
A previously healthy 4 year old Caucasian girl presented
with 9 days of fever, diffuse maculopapular rash,
conjunctival injection without exudate, erythema of the
hands and feet with periungual desquamation, and oral
mucosal changes. The patient was diagnosed with KD
and treated with IVIG. Approximately, 50 h after com-
pletion of the 1
st IVIG, the patient was given a 2
nd infu-
sion of IVIG for recrudescence of fever. Prior to the 2
nd
dose of IVIG, she was evaluated for hemolytic anemia
because of a drop in hemoglobin (see Table 2). At that
time, she had a normal LDH and bilirubin, as well as a
negative direct antiglobulin test. Unfortunately, signifi-
cant hemolytic anemia occurred following the 2
nd dose
of IVIG. This was noted 48 h following the completion
of the 2
nd IVIG (see Table 1). The patient made a good
clinical recovery without cardiovascular complications of
KD.
Case 3
A previously healthy 16-year old Asian male presented
with 8 days of fever, diffuse maculopapular rash, con-
junctival injection without exudate, erythema and edema
Table 1 Clinical characteristics and laboratory investigation in KD patients with hemolytic anemia following IVIG
Case 1 Case 2 Case 3 Case 4
Gender Male Female Male Male
Age at diagnosis 22 months 4 years 16 years 7 months
Duration of fever before treatment 13 days 9 days 8 days 5 days
Clinical criteria of KD 4/5 4/5 4/5 4/5
Hemoglobin (g/L) before 1
st IVIG 94
(115-135)
117
(115-155)
114
(130-160)
93
(105-135)
Lowest hemoglobin (g/L) after 2
nd IVIG 65 64 56 56
Blood group A Rh(D) pos A Rh(D) pos B Rh(D) pos AB Rh(D) pos
Direct antiglobulin test baseline (IgG) ND* Negative Negative ND*
Direct antiglobulin test after hemolysis (IgG) Positive Positive Positive Positive
Antibody identified in red blood cell eluate Anti-A ND* Anti-B Anti-A, Anti-B
LDH (U/L) 660
(470-920)
522
(142-297)
1881
(340-750)
495
(140-304)
Indirect bilirubin (umol/L) 12 (0-34) 20 (0-34) 55 (0-19) 29 (0-34)
Haptoglobin (0.69 - 1.96 g/L) 3.44 ND* 0.06 0.38
Significant spherocytosis Yes Yes Yes Yes
Reticulocyte count (0.2 - 2%) 13.1 12.2 4.7 2.4
Blood transfusion No No Yes Yes
Coronary outcome CAA Normal Normal CAA
ND* Not Done; CAA coronary artery aneurysm
Table 2 Hemoglobin in KD patients with hemolytic anemia following IVIG
Case 1 Case 2 Case 3 Case 4
Hemoglobin (g/L)
Before 1
st IVIG
94
(115-135)
117
(115-155)
114
(130-160)
93
(105-135)
Hemoglobin (g/L)
Before 2
nd IVIG
ND 91* 102 86
Hemoglobin (g/L)
24-48 hours after 2
nd IVIG
65 74
(64 - at 72 h)
56 56
ND Not Done; *Suspected hemolysis prior to 2
nd IVIG however, work-up was negative
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course was complicated by myocarditis, requiring inten-
sive care unit admission and inotropic support, chole-
static hepatitis and pancreatitis. Extensive infectious
disease work-up was negative. The patient was diag-
nosed with KD. Given his atypical presentation, the
diagnosis was made only after an extensive work-up
excluding other possible diagnoses. He was treated with
IVIG. A 2
nd infusion of IVIG was given 72 h later for
recrudescence of fever. Towards the end of the 2
nd IVIG
infusion, the patient developed “tea-colored” urine.
Hemolytic anemia was suspected and confirmed (see
Tables 1 and 2). A few days later, he required a red cell
transfusion for hemodynamic instability secondary to
hemolytic anemia. Intravenous pulse methylprednisolone
(30 mg/kg) was also given for persistent fever. On fol-
low-up, he developed typical periungual desquamation
associated with KD. He made a good clinical recovery
without cardiovascular complications.
Case 4
A previously healthy 7-month old Caucasian boy pre-
sented with 5 days of fever, diffuse maculopapular rash,
conjunctival injection without exudate, erythema of the
hands and feet and oral mucosal changes. The patient was
diagnosed with KD and treated with IVIG. Approximately
42 h after completion of the first IVIG, he was given a 2
nd
infusion of IVIG for persistence of fever. Patient was
noted to be very pale and lethargic approximately 8 h after
the 2
nd IVIG was completed. Significant hemolytic anemia
was confirmed (see Tables 1 and 2). Due to hemodynamic
instability and difficulty with vascular access, he required
intraoperative placement of an intravenous line for receipt
of a red cell transfusion. Two weeks following the diagno-
sis of KD, a small right coronary artery aneurysm (3.0
mm) was noted that resolved after 2 months.
Discussion
Hemolytic anemia is a potentially serious and possibly
under recognized side effect of IVIG therapy. The pre-
sence of transient, passively acquired antibodies (positive
direct antiglobulin test) with associated decreased hapto-
globin levels and mild reticulocytosis following treat-
ment with IVIG was noted many years ago [9].
However, this rarely results in clinically significant ane-
mia. There have only been 4 previous reports with a
total of 6 patients described to have hemolysis following
IVIG therapy for KD [4-7]. In all 4 reports, the pre-
sumed mechanism was of a direct antibody mediated
attack, but they only demonstrated specific blood group
antibodies in 4 of 6 of these patients [4-7] We found
antibodies in the eluate of the 3 patients that were
tested; in addition, all 4 patients had a positive direct
antiglobulin test (see Table 1). To our knowledge this is
the largest case series that demonstrated specific blood
group antibodies following IVIG for Kawasaki disease,
which further supports the hypothesis that direct anti-
body mediated attack is one of the potential mechan-
isms for hemolysis in this population.
The etiology of clinically significant hemolysis in
patients with KD treated with IVIG is multifactorial. Iso-
hemagglutinins (anti-A/B antibodies) present in IVIG
can cause direct antibody attack on RBCs. Even though
the titers of these antibodies, in commercially available
products, must meet agreed-upon specifications by man-
ufacturers through a Biologics Licence Application [3],
there are many documented cases of hemolytic anemia
despite these limits [10]. This phenomenon may be dose
dependent given that in 6 of the 6 patients previously
reported, and in all 4 of our patients (total 10/10
patients), acute hemolytic anemia occurred following a
second dose of IVIG for persistent fever. All patients
received a total of 4 g/kg prior to the clinically significant
hemolysis. However, it is known that hemolytic anemia
can occur even with doses as low as 1 g/kg [10]. Factors
that may increase the risk for hemolysis include the dose
of IVIG, the titer of the isohemagglutinin antibody in the
IVIG preparation, the strength of the patient’sa n t i g e n
expression [5,7], the affinity of the antibody for the anti-
gen [7], or a combination of these factors.
All our KD patients received Gammunex. Hemolytic
anemia in KD has also been reported with Gammaguard
[7]. Isosmolar, liquid IVIG products, such as Gamma-
guard and Gammunex, seem to have higher isohemag-
glutinin titers than lyophilized products [10]. However,
lyophilized products are more osmolar and have other
potential side effects including acute renal failure and
thrombosis [10].
There is a greater risk for hemolysis in patients with
non-O blood groups [10]. It is hypothesized that
patients with non-O blood groups, with low concentra-
tions (congenital or acquired) of soluble A and/or B
substance in their plasma, are at increased risk for
hemolysis due to their inability to neutralize the anti-A
and/or anti-B isohemagglutinins present in the plasma
after IVIG infusion [11]. What is interesting about this
hypothesis is that in all KD patients who developed
hemolysis following IVIG (including our patients), the
b l o o dt y p ei n6w a sA + ,2A B + ,1B+a n d1O + .T h e
patient who was O + also had cold agglutinins.
It is also plausible that patients with a baseline ane-
mia, as is often seen in KD, may be more susceptible to
hemolysis because of an absolute decrease in binding
sites to disperse the antibodies. Other potential causes
for hemolysis in KD include cold agglutinating anti-RBC
antibodies [4]. KD in itself may also be a predisposing
factor for hemolysis given that there is immune dysregu-
lation in this disease. This is supported by case reports
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receive IVIG [12,13].
Another possible mechanism for a decrease in hemo-
globin with IVIG, independent of isoantibodies, is
enhanced erythrocyte sequestration [14]. Since IVIG
contains high molecular weight IgG complexes, these
can mimic immune complexes by activating comple-
ment [14]. These complexes bind to complement recep-
tor 1 on RBCs which leads to erythrophagocytosis and
hence a reduction in hemoglobin [14]. Predictors for
this phenomenon include age and RBC ability to bind
the IVIG immune complex-like moieties [14].
In Canada, the prevalence of hemolysis following IVIG
is unknown given the underdeveloped surveillance sys-
tem of IVIG administration. However, in recent years,
the Canadian Blood Services and Hema-Quebec have
noted an increase in reporting of this complication [15].
We witnessed an unusually high rate (16%) of clini-
cally significant hemolysis over a 14-month period at
our institution and this complication had not been
noted previously. We are unaware of any important
changes that occurred in the IVIG product during this
time period to account for these findings. At the same
time, we experienced a high retreatment rate and there-
fore we cannot exclude subtle changes in the IVIG pro-
duct that could explain both these findings. Specific
blood group antibodies were demonstrated in addition
to the positive direct antiglobulin test, which suggests
that the primary mechanism for hemolysis in our cases
was through direct antibody mediated attack.
Conclusions
Hemolytic anemia should be considered in patients with
KD treated with high dose IVIG who experience a drop
in hemoglobin following treatment and/or who develop
clinical signs of hemolysis.I ti si m p o r t a n tt h a tp h y s i -
cians are aware of this potential complication for early
recognition as well as for disclosing this potential side
effect to patients and their families. It is now our rou-
tine practice to monitor the hemoglobin 24 to 48 h after
completion of IVIG and one week after discharge, parti-
cularly if retreatment is necessary. A work up for hemo-
lysis is not routinely required except if this complication
is suspected. Families shou l db ei n f o r m e dt or e t u r n
should their child develop pallor, lethargy, dark urine,
shortness of breath or palpitations. Further insight is
still required in regards to the pathogenesis and predis-
posing factors for hemolysis in this patient population.
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